Open-Angle Glaucoma - Pipeline Insight, 2026

DelveInsight’s, “Open-Angle Glaucoma - Pipeline Insight, 2026” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Open-Angle Glaucoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Open-Angle Glaucoma: Understanding

Open-Angle Glaucoma: Overview

Open angle glaucoma is a chronic, progressive, and irreversible optic neuropathy that represents the most common form of glaucoma. It is defined by an anatomically open anterior chamber angle and characteristic structural changes of the optic nerve head and retinal nerve fiber layer. In this condition, the drainage angle between the cornea and iris remains open, but altered outflow dynamics contribute to damage of the optic nerve and gradual visual field loss. This disease occurs when the eye’s natural drainage system, responsible for maintaining normal fluid balance, becomes partially blocked. Resistance develops within the trabecular meshwork which is a spongy tissue that facilitates fluid outflow. This impaired drainage leads to a gradual buildup of intraocular fluid, which over time increases pressure inside the eye and can damage the optic nerve, the structure responsible for transmitting visual information from the eye to the brain. Open angle glaucoma can be classified into primary and secondary forms. In primary open angle glaucoma, there is no obvious underlying cause, and the increased resistance to fluid drainage appears to result from age related changes in the trabecular meshwork—such as loss of cells and decreased function—leading to gradual buildup of fluid and increased intraocular pressure. In contrast, secondary open angle glaucoma occurs when another condition directly contributes to or accelerates the dysfunction of the drainage system; for example, swelling, protein deposits, or cellular debris can clog the outflow pathways and raise eye pressure

The symptoms of open angle glaucoma include gradual loss of peripheral vision, difficulty in seeing objects at the edges of the visual field, missing letters when reading, and reduced visual contrast in low-light conditions. Most people do not notice these changes in the early stages, which is why the disease can progress silently and cause irreversible vision loss before being detected. Regular comprehensive eye examinations are therefore essential for early diagnosis.

The treatment of open angle glaucoma aims to lower intraocular pressure to prevent optic nerve damage. This is primarily achieved with eye drops such as prostaglandin analogs, beta-blockers, or carbonic anhydrase inhibitors, which either increase aqueous outflow or reduce aqueous production. When medical therapy is insufficient or poorly tolerated, laser treatments like laser trabeculoplasty can improve drainage, and surgical options—including trabeculectomy, glaucoma drainage devices, and minimally invasive glaucoma surgeries—are used to achieve greater or sustained pressure reduction.

""Open-Angle Glaucoma- Pipeline Insight, 2026"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Open-Angle Glaucoma pipeline landscape is provided which includes the disease overview and Open-Angle Glaucoma treatment guidelines. The assessment part of the report embraces, in depth Open-Angle Glaucoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Open-Angle Glaucoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Open-Angle Glaucoma R&D. The therapies under development are focused on novel approaches to treat/improve Open-Angle Glaucoma.

Open-Angle Glaucoma Emerging Drugs Chapters

This segment of the Open-Angle Glaucoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Open-Angle Glaucoma Emerging Drugs

• HUC3-637: Huons Co., Ltd.

HUC3-637 is an investigational ophthalmic drug developed by Huons Co., Ltd. for the treatment of primary open-angle glaucoma and ocular hypertension. it is a fixed-dose combination of dorzolamide, a carbonic anhydrase inhibitor, and timolol, a beta-blocker, formulated as a topical eye drop. The drug is designed to reduce intraocular pressure (IOP), the primary risk factor associated with glaucoma progression, by decreasing aqueous humor production through dual mechanisms. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Open-Angle Glaucoma.

• QLS111: Qlaris Bio, Inc.

QLS-111, a novel formulation built on an ATP-sensitive potassium (KATP) channel modulator platform. The drug is designed to reduce intraocular pressure (IOP) by relaxing blood vessels and vascular-like tissues located distal to the trabecular meshwork. This mechanism decreases distal outflow resistance and lowers episcleral venous pressure (EVP), which plays a critical role in overall IOP regulation. Clinical studies have demonstrated that QLS-111 provides sustained IOP reduction both as a monotherapy and in combination with standard treatments such as latanoprost, showing additive efficacy. The drug has also exhibited a favorable safety and tolerability profile, with no significant hyperemia or serious adverse events reported. Currently, the drug is being evaluated in the Phase II/III stage of its development for the treatment of Open-Angle Glaucoma.

• Xelafaslatide (ONL1204): ONL Therapeutics

Xelafaslatide (ONL1204) is a first-in-class small peptide that effectively inhibits the Fas receptor, thus blocking the activation of the Fas pathway and the related immune signaling which results in the death of key retinal cells and loss of vision. By blocking Fas activation, ONL1204 prevents downstream cell death signaling and inflammatory responses, thereby preserving critical retinal cells such as photoreceptors and retinal ganglion cells. Clinical studies, including Phase 1b trials, have demonstrated that ONL1204 is generally safe and well tolerated, with early evidence suggesting its potential to slow disease progression, such as reducing lesion growth in geographic atrophy. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Open-Angle Glaucoma.

• IVW-2001 (GVB-2001): iVIEW Therapeutics, Inc.

IVW-2001 (GVB-2001) is a first-in-class gene therapy candidate developed by IVIEW Therapeutics for primary open-angle glaucoma. It is also the world’s first glaucoma gene therapy designed for all POAG patients without stratifying by genetic subtype. The product utilizes an optimized self-complementary AAV vector delivered by a single intracameral injection directly to the trabecular meshwork, the anatomical core of aqueous outflow obstruction in glaucoma. By modulating cellular function and enhancing aqueous humor outflow, GVB-2001 enables rapid, durable IOP control, intervenes at the level of disease mechanism, and aims to reduce irreversible optic nerve damage at its source. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Open-Angle Glaucoma.

Further product details are provided in the report……..

Open-Angle Glaucoma: Therapeutic Assessment

This segment of the report provides insights about the different Open-Angle Glaucoma drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Open-Angle Glaucoma

There are approx. 18+ key companies which are developing the therapies Open-Angle Glaucoma. The companies which have their Open-Angle Glaucoma drug candidates in the most advanced stage, i.e. Phase III include, Huons Co., Ltd., and others.

• Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Open-Angle Glaucoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Open-Angle Glaucoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Open-Angle Glaucoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Open-Angle Glaucoma drugs.

Open-Angle Glaucoma Report Insights

• Open-Angle Glaucoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Open-Angle Glaucoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Open-Angle Glaucoma drugs?
• How many Open-Angle Glaucoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Open-Angle Glaucoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Open-Angle Glaucoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Open-Angle Glaucoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Huons Co., Ltd.
• Qlaris Bio, Inc.
• OLN Therapeutics
• iVIEW Therapeutics, Inc.
• Ocular Therapeutix, Inc.
• Alcon Research
• Nicox Ophthalmics, Inc.
• Bausch & Lomb Incorporated
• Glaukos Corporation
• Huons Co., Ltd.
• Omikron Italia S.r.l.

Key Products

• HUC3-637
• QLS-111
• Xelafaslatide (ONL1204)
• IVW-2001 (GVB-2001)
• OTX-TIC
• AR-17043 Ophthalmic Solution
• NCX 470
• BL1107
• GLK-311
• WB007
• HUC3-637
• Citicoline

Show more